跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
METOJECT SUBCUTANEOUS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
METOJECT SUBCUTANEOUS
Authorized
STANDARD
METOJECT SUBCUTANEOUS
medexus pharmaceuticals inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
b45173d48ed5b7f3
Company
medexus pharmaceuticals inc.
Type
Standard
Approval Details
Approval Id
b45173d48ed5b7f3
Drug Approval Canada Name
METOJECT SUBCUTANEOUS
Product Name
METOJECT SUBCUTANEOUS
Status
Marketed
Status Date
2019-09-16
Original Market Date
2019-09-16
Din
02454750
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L04AX03 METHOTREXATE
Atc Name
l 04 ax 03
Aig Number
0107545005
Company Name
medexus pharmaceuticals inc.
Company Address
35 Nixon Road, Unit 10, Bolton, Ontario, Canada, L7E 1K1
Active Ingredients
METHOTREXATE (METHOTREXATE SODIUM)
12.5 MG / 0.25 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
b45173d48ed5b7f3
Type
Standard
Back to Health Canada Approvals